While Celgene Corp. and bluebird bio Inc. have the most advanced BCMA-targeting chimeric antigen receptor T-cell (CAR-T) therapy in the clinic for the treatment of relapsed or refractory multiple myeloma, data presented at the American Society of Hematology (ASH) meeting on Dec. 3 in San Diego show that CAR-T therapies against the same target from Poseida Therapeutics Inc., partners Legend Biotech Corp. and Janssen Pharmaceutical Cos., and others are quickly gaining ground.
Poseida, Legend/Janssen Look To Snag Celgene/Bluebird's BCMA Crown
Poseida and Legend/Janssen aim to develop CAR-T therapies with improved efficacy and safety, and both programs delivered updates at ASH for BCMA-targeting CAR-T candidates in multiple myeloma that could challenge Celgene/bluebird's lead in this field.
More from Clinical Trials
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
More from R&D
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.